CAS: 180695-79-8; N-Boc-4-Bromopiperidine

相似化合物

54288-70-9 76444-51-4 301665-60-1

上下游产品

CAS号24424-99-5 二碳酸二叔丁酯 | CAS号54288-70-9 4-溴哌啶 氢溴酸盐 | CAS号109384-19-2 N-B°C-4-羟基哌啶 | CAS号558-13-4 四溴化碳 | CAS号90633-18-4 1-PYRAZIN-2-YL-... | CAS号180695-80-1 4-叠氮哌啶-1-羧酸叔丁酯 | CAS号87120-72-7 1-B°C-4-氨基哌啶 | CAS号123387-49-5 4-苯基-1-哌啶羧酸叔丁酯 | CAS号1048970-17-7 1-N-叔丁氧羰基哌啶-4-硼酸频哪醇酯 | CAS号220394-97-8 N-B°C-4-CBZ-氨基哌啶 | CAS号690261-78-0 4-(3-Thienyl)-1... | CAS号550371-77-2 4-(3-Pyridinyl)...

N-Boc-4-羟基哌啶置于咪唑,溴,三苯基膦体系中,用 二氯甲烷 用作溶剂,化学反应生成4-溴-N-Boc-哌啶
参考文献:镍催化的烷基卤化物根岸交叉偶联,包括未活化的叔卤化物,与硼稳定的有机锌试剂
标题:镍催化的烷基卤化物根岸交叉偶联,包括未活化的叔卤化物,与硼稳定的有机锌试剂
摘要:未活化的叔烷基亲电子试剂与烷基金属试剂的镍催化交叉偶联仍然是一个挑战.我们在此报告了镍催化的烷基卤化物(包括未活化的叔卤化物)与硼稳定的有机锌试剂 Bpinch 2 Zni 的根岸交叉偶联,产生具有高官能团耐受性的多功能有机硼产品.重要的是,发现 Bpin 基团对于进入季碳中心是必不可少的.制备的季有机硼酸盐的合成实用性通过它们转化为其他有用的化合物来证明.
Doi:10.1021/acs.Orglett.3C00051

专利信息

专利号:US-2024261416-A1
优先权日:2023-01-31
标题:Synthesis of novel cereblon e3 ligase ligands, compounds formed thereby, and pharmaceutical compositions containing them
发明人：TANG WEIPING; XIE HAIBO; WU YUNXIANG; LIAO JUNZHUO; LI CHUNRONG; TANDON IRA; TANG HUA
权利人:WISCONSIN ALUMNI RES FOUND
摘要:Provided herein are achiral cereblon (CRBN) ligands based on phenyl dihydrouracil that have optimal binding to CRBN without having chiral carbons. Also provided herein are the proteolysis targeting chimeras (PROTACs) comprising the CRBN ligands and a protein binder, pharmaceutical compositions containing the PROTACs, and methods of treating diseases using the PROTACs.

专利号:WO-2023131254-A1
优先权日:2022-01-06
标 题 :Pseudouridine modified at n1 position and use thereof in mrna synthesis
发明人：LI SONG; GUO CHUANXIN; CAI XIAORU; QIAN QIJUN
权利人:MAXIRNA SHANGHAI PHARMACEUTICAL CO LTD; MAXIRNA ZHEJIANG TECH CO LTD
摘要:Provided in the present invention are a pseudouridine modified at an N1 position and the use thereof in mRNA synthesis. Specifically, the compound of the present invention comprises compounds represented by formula I and formula II, and the definition of each group in the formula is as described herein. The compound of the present invention can be used for preparing mRNA to reduce the autoimmunogenicity of the mRNA, improve the stability of the mRNA itself, and/or enhance the expression time and expression efficiency of the mRNA in a target cell.